Canadian buyers get a different legal answer from American buyers, because Canada regulates this category through a different door: not a control list, but the natural health product (NHP) framework. As of September 2026 the practical picture is workable but specific, and this post is the breakdown. Standing caveats: general information, not legal advice; regulatory positions change; verify the current status before ordering. The US side of the map is in the state overview.
The three parts of the Canadian answer
- Kratom is not under the CDSA. The Controlled Drugs and Substances Act is the federal control list, and Mitragyna speciosa — its leaf, extracts, and natural alkaloids — is not listed there. Possession of kratom and its alkaloids for personal use is not a criminal offense under the CDSA. That is the baseline, and it holds for 7-hydroxymitragynine as a kratom alkaloid: there is no CDSA schedule entry that reaches it directly.
- Health Canada has not authorized kratom as an NHP. This is the part that catches people: because Health Canada treats kratom as an unauthorized natural health product, it cannot be legally sold or marketed for human consumption. No Natural Product Number (NPN), no approved health claims — vendors operating in the Canadian market do so under botanical/research framing, and no company is authorized to sell kratom or its alkaloids as a consumable product. The CFIA and Health Canada have enforced against vendors making consumption claims, including seizures.
- There is no province-level ban. The status is set federally; no province has enacted an outright ban on possession. Provincial differences show up in enforcement attention, local health-unit guidance, and (in Quebec) bilingual labeling requirements — not in the baseline legality. CBSA does not classify kratom as a prohibited import, though commercial importers face the labeling and documentation requirements.
How this differs from the US picture
| United States | Canada | |
|---|---|---|
| Control list | DEA federal + state’schedules (7-OH not scheduled; threshold rule pending; related alkaloids scheduled Aug 26 2026) | CDSA — kratom and its alkaloids not listed |
| The binding restriction | State statutes (7 restricted states as of Sept 2026) | NHP authorization — sale/marketing for human consumption is the restricted activity |
| What the vendor must do | Not sell into restricted states; 21+ verification | Not sell or market for human consumption; compliant labeling; no health claims |
| What the buyer faces | State-specific possession questions | A possession baseline that is clear; a sales-channel framework that is specific |
The structural difference matters: the US picture is a list of places you cannot be, and the Canadian picture is a set of rules about how the product may be sold and represented. Both have real edges — the Canadian edge is the consumption-marketing restriction, and the US edge is the state map plus the pending federal threshold rule covered in the federal status guide.
What it means for a Canadian buyer
- The possession baseline is clear; the sales framework is specific. Buying for personal use sits on the CDSA baseline, while the product’s labeling and the vendor s representation must respect the NHP restriction. Compliant vendors are explicit about this framing — a vendor making consumption claims in the Canadian market is operating outside its own regulatory position, and that is a flag about everything else the vendor does.
- Check the current Health Canada position before ordering. The NHP framework is under continuous review, and Health Canada’s posture on novel consumption products has been active. The legal status guide tracks the position, and a current check of Health Canada’s published guidance is five minutes that keep the decision correct.
- Verify the batch regardless. The verification habits are the same on both sides of the border: batch COA matched to the pack, related-compound screens clean (the scheduled-analog context from the DEA update is the US version of the same hygiene standard), and the batch verification process followed.
- Use the same responsible-use rules. Spacing, real breaks, no mixing with depressants, 21+ only — the responsible use guide applies everywhere the product is lawfully held.
Our position on Canadian orders: we handle them within the current regulatory framework and the shipping policy, with 21+ verification and the same batch-COA documentation on every pack. If you are a Canadian buyer, the contact page is the place to confirm the current shipping position for your province before ordering — the framework is specific enough that a current check beats an assumption.
Bottom line
Canada in 2026: not on the CDSA control list, Health Canada’s NHP restriction on sale for human consumption is the binding edge, no province-level bans, and a vendor framework that rewards compliance. The Canadian buyer s position is workable and clearer than it is in most of the US — with the standing habit of verifying the current Health Canada position and the batch on every pack. The FAQ center carries the standing shipping and legality questions, and the state map covers the US side for cross-border situations.